市場調查報告書

胃輕癱 - 市場調查,流行病學,市場預測 2028年

Gastroparesis Market Insights, Epidemiology, and Market Forecast - 2028

出版商 DelveInsight Business Research LLP 商品編碼 401819
出版日期 內容資訊 英文 193 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
胃輕癱 - 市場調查,流行病學,市場預測 2028年 Gastroparesis Market Insights, Epidemiology, and Market Forecast - 2028
出版日期: 2019年12月01日內容資訊: 英文 193 Pages
簡介

胃輕癱,也稱為胃排空延遲,是一種消化系統疾病,會減緩或阻止食物從胃到小腸的運動, 造成胃液和食物殘留在胃內部的胃排放障礙。胃輕癱的典型性症狀有腹脹,噁心,胃酸逆流,上腹疼痛等。這些症狀常被稱作消化不良。

本報告提供主要7個國家(美國,英國,德國,法國,義大利,西班牙,日本)的胃輕癱市場相關調查,總括性彙整疾病概要和現行的治療方法,新藥的簡介,主要7個國家的市場趨勢,流行病學的預測,市場規模,患病數·罹患數的變化與預測,未滿足需求,市場成長要素及障礙等資訊。

目錄

第1章 簡介

第2章 市場概要

  • 市場佔有率(實際成果值)
  • 市場佔有率(預測值)

第3章 疾病背景和概要:胃輕癱

  • 簡介
  • 症狀
  • 病因
  • 危險因素
  • 病理學
  • 診斷
  • 治療

第4章 流行病學和患者人口

  • 主要調查結果
  • 主要7個國家胃輕癱的整體患病數/罹患數
  • 主要7個國家胃輕癱的整體患病數 - 各國

第5章 胃輕癱的流行病學:各國

  • 美國
    • 假設和理論的根據
    • 患病數·罹患數
    • 病例數:各類型
    • 病例數:性別
    • 診斷數量
    • 可治療的病例數
  • 歐盟5國
    • 假設和理論的根據
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本

第6章 現行治療

  • 治療流程
  • 治療指南

第7章 未滿足需求

第8章 已上市治療藥

  • 醫藥品 A
    • 醫藥品概要
    • 作用機制
    • 法規的里程碑
    • 優點與缺點
    • 產品簡介
  • 醫藥品 B

第9章 開發平台治療療藥

第10章 主要交叉對比

第11章 新藥

  • 醫藥品 C
    • 醫藥品概要
    • 臨床試驗詳細內容
    • 安全性和有效性
    • 優點與缺點
    • 開發平台開發趨勢
    • 產品簡介
  • 醫藥品 D

第12章 市場分析胃輕癱:主要7個國家

  • 市場規模
  • 已上市治療藥的市場佔有率
  • 各產品的銷售量

第13章 胃輕癱:各國市場分析

  • 美國
    • 市場規模
    • 已上市治療藥的市場佔有率
    • 各產品的銷售量
    • 新藥分析及其對市場的影響
  • 歐盟5國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本

第14章 市場成長要素

第15章 市場障礙

第16章 附錄

第17章 調查手法

  • 出處

第18章 DelveInsight的服務內容

第19章 免責聲明

第20章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIMI0086

DelveInsight's 'Gastroparesis Market Insights, Epidemiology, and Market Forecast-2028' report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Gastroparesis in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2028

Gastroparesis-Disease Understanding and Treatment Algorithm

Gastroparesis, which is a translated meaning of "stomach paralysis", is a digestive disorder characterized by delayed gastric emptying of solid food in the absence of mechanical obstruction of the stomach, resulting in the cardinal symptoms of early satiety, postprandial fullness, nausea, vomiting, belching and bloating. It is now recognized as part of a broader spectrum of gastric neuromuscular dysfunction that includes impaired gastric accommodation. The overlap between the symptoms, of Gastroparesis and other disorders such as functional dyspepsia, makes the diagnosis of Gastroparesis difficult.

According to the American Diabetes Association, Gastroparesis is a disorder affecting people with both type 1 and type 2 diabetes, in which the stomach takes too long to empty its contents (delayed gastric emptying). The vagus nerve controls the movement of food through the digestive tract. If this nerve is damaged or stops working, the muscles of the stomach and intestines do not work normally, and the movement of food is slowed or stopped. Just as with other types of neuropathy, diabetes can damage the vagus nerve if blood glucose levels remain high over a long period. High blood glucose causes chemical changes in nerves and damages the blood vessels that carry oxygen and nutrients to the nerves.

The etiology of Gastroparesis include diabetic, postsurgical, Iatrogenic, surgical and idiopathic as these are major causes of gastroparesis. Based on the causes, Gastroparesis is divided into three major types, i.e., Idiopathic gastroparesis, Diabetic gastroparesis, and Post-surgical gastroparesis. Some of the researchers proposed a classification system to help determine appropriate treatment options such as Grade 1, or mild gastroparesis, is characterized by symptoms that come and go and can easily be controlled by dietary modification and by avoiding medications that slow gastric emptying. Grade 2, or compensated gastroparesis, is characterized by moderately severe symptoms. Individuals with Grade 2 Gastroparesis are treated with medications that stimulate gastric emptying and medications that reduce vomiting; such individuals require hospitalization only infrequently. Grade 3, or gastric failure, is characterized by individuals who do not respond to medications used to treat gastroparesis. These individuals cannot maintain proper nutrition or hydration. Required therapies may include intravenous fluids and medications and nutrition, or surgery. Individuals with Grade 3 Gastroparesis often require hospitalization.

The treatment of Gastroparesis is based on the severity of symptoms of the disease. If diabetes is associated with gastroparesis, then treatment is done by controlling blood glucose levels. The treatment of Gastroparesis mainly includes nonpharmacological steps, such as dietary modification, and pharmacological measures, including medications that stimulate gastric emptying (prokinetics), medications that reduce vomiting (antiemetics), medications for controlling pain and intestinal spasms, and surgery.

Gastroparesis Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Prevalence of Gastroparesis, Gender-Specific Prevalence of Gastroparesis, Severity-Specific Prevalence of Gastroparesis, Type-Specific Prevalence of Gastroparesis, and Total Diagnosed Prevalent Population of Gastroparesis] scenario of Gastroparesis in the 7MM Countries covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2028.

DelveInsight's analysts have assessed that the total prevalent population of Gastroparesis in the 7MM was 33,690,400 in 2017. In addition to this, it was accessed that the total diagnosed prevalent population of Gastroparesis in the 7MM was assessed to be 16,845,200 in 2017.

Gastroparesis Drug Chapters

Gastroparesis is a complex, debilitating dysmotility disorder with challenging symptom management. Given the limited efficacy of treatment options and serious side effects, significant research continues for therapeutic options for Gastroparesis.

The treatment landscape of Gastroparesis comprises of very few pharmacotherapies. The usual treatments for Gastroparesis include nutritional assessment, dietary modifications, and Pharmacological Therapies. Pharmacological therapies include Prokinetic Agents, Antiemetic Agents (off-label), and Antianxiety Benzodiazepine Agents (off-label). Apart from these Pharmacological therapies, Electrical Stimulation Therapies, Endoscopic Therapies, and Surgical Therapies are used for the treatment management of Gastroparesis. The primary aim of present therapies is to improve the efficiency of the gastric pump and to relieve symptoms of nausea, bloating, vomiting, and pain. The selection of recommended drugs is based on the severity of the symptoms (grades).

"According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Metoclopramide, Domperidone, Erythromycin, Antiemetics, Antidepressants, and Pain medicines are helpful for the treatment of Gastroparesis and associated symptoms."

Gastroparesis Market Outlook

The market size of Gastroparesis in seven major markets (7MM) is estimated to be USD 3,414.16 million in 2017. The United States accounts for the highest market size of Gastroparesis,i.e. USD 1,558.41 million, in comparison to the other major markets i.e., EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan. Among the EU5 countries, Germany had the highest market size in 2017, while the UK had the lowest market size of Gastroparesis in 2017.

Gastroparesis Drugs Uptake

With the launch of emerging therapies like Gimoti (EVK-001, a product of Evoke Pharma), which is a metoclopramide nasal spray, Relamorelin (Allergan), Tradipitant (Vanda Pharmaceuticals), Velusetrag (Theravance Biopharma), and CIN-102 (Deuterated Domperidone, CinRX Pharma), the market of Gastroparesis is anticipated to change during the forecast period (2019-2028).

Products that are anticipated to be launched during the forecast period are in late clinical stages of development, while others are in ongoing late clinical development stages. Some of the above-mentioned drug candidates have shown very promising results and it has been anticipated by DelveInsight's analysts that completion of clinical development and launch of these products in the market, might increase the market share of these companies, and besides this, patients of Gastroparesis will have better management practices.

According to our assessment, potential emerging candidates shall launch in the upcoming years of the forecast period [2019-2028], and with their anticipated launch, the market size of Gastroparesis will also experience significant growth.

Gastroparesis Report Insights

  • Total Prevalence of Gastroparesis
  • Gender-Specific Prevalence of Gastroparesis
  • Severity-Specific Prevalence of Gastroparesis
  • Type-Specific Prevalence of Gastroparesis
  • Total Diagnosed Prevalent Population of Gastroparesis
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Gastroparesis Report Key Strengths

  • 10-Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Gastroparesis Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Gastroparesis market
  • Organize sales and marketing efforts by identifying the best opportunities for Gastroparesis market
  • To understand the future market competition in the Gastroparesis market.

Table of Contents

1. Key Insights

2. Gastroparesis: Market Overview at a Glance

  • 2.1. Total Market Share (%) Distribution of Gastroparesis in 2017
  • 2.2. Total Market Share (%) Distribution of Gastroparesis in 2028

3. Gastroparesis: Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Types of Gastroparesis: Based on Causes
    • 3.2.1. Idiopathic Gastroparesis (IG)
    • 3.2.2. Diabetic Gastroparesis (DGp)
    • 3.2.3. Iatrogenic and Postsurgical Gastroparesis
  • 3.3. Clinical Signs and Symptoms
  • 3.4. Mechanisms or Pathophysiology of Gastroparesis
  • 3.5. Diagnosis of Gastroparesis

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Total Prevalence of Gastroparesis in the 7MM
  • 4.3. Type-Specific Prevalence of Gastroparesis in the 7MM
  • 4.4. Gender-Specific Prevalence of Gastroparesis in the 7MM
  • 4.5. Severity Specific Prevalence of Gastroparesis in the 7MM
  • 4.6. Total Diagnosed Prevalent Population of Gastroparesis in the 7MM

5. United States Epidemiology

  • 5.1. Assumptions and Rationale
  • 5.2. Total Prevalence of Gastroparesis in the United States
  • 5.3. Type-Specific Diagnosed Prevalence of Gastroparesis in the United States
  • 5.4. Gender-Specific Prevalence of Gastroparesis in the United States
  • 5.5. Severity Specific Prevalence of Gastroparesis in the United States
  • 5.6. Total Diagnosed Prevalence of Gastroparesis in the United States

6. EU5 Epidemiology

  • 6.1. Germany Epidemiology
    • 6.1.1. Total Prevalence of Gastroparesis in Germany
    • 6.1.2. Type-Specific Prevalence of Gastroparesis in Germany
    • 6.1.3. Gender-Specific Prevalence of Gastroparesis in Germany
    • 6.1.4. Severity Specific Prevalence of Gastroparesis in Germany
    • 6.1.5. Total Diagnosed Prevalence of Gastroparesis in Germany
  • 6.2. France Epidemiology
    • 6.2.1. Total Prevalence of Gastroparesis in France
    • 6.2.2. Type-Specific Prevalence of Gastroparesis in France
    • 6.2.3. Gender-Specific Prevalence of Gastroparesis in France
    • 6.2.4. Severity Specific Prevalence of Gastroparesis in France
    • 6.2.5. Total Diagnosed Prevalence of Gastroparesis in France
  • 6.3. Italy Epidemiology
    • 6.3.1. Total Prevalence of Gastroparesis in Italy
    • 6.3.2. Type-Specific Prevalence of Gastroparesis in Italy
    • 6.3.3. Gender-Specific Prevalence of Gastroparesis in Italy
    • 6.3.4. Severity Specific Prevalence of Gastroparesis in Italy
    • 6.3.5. Total Diagnosed Prevalence of Gastroparesis in Italy
  • 6.4. Spain Epidemiology
    • 6.4.1. Total Prevalence of Gastroparesis in Spain
    • 6.4.2. Type-Specific Prevalence of Gastroparesis in Spain
    • 6.4.3. Gender-Specific Prevalence of Gastroparesis in Spain
    • 6.4.4. Severity Specific Prevalence of Gastroparesis in Spain
    • 6.4.5. Total Diagnosed Prevalence of Gastroparesis in Spain
  • 6.5. United Kingdom Epidemiology
    • 6.5.1. Total Prevalence of Gastroparesis in the United Kingdom
    • 6.5.2. Type-Specific Prevalence of Gastroparesis in the United Kingdom
    • 6.5.3. Gender-Specific Prevalence of Gastroparesis in the United Kingdom
    • 6.5.4. Severity Specific Prevalence of Gastroparesis in the United Kingdom
    • 6.5.5. Total Diagnosed Prevalence of Gastroparesis in the United Kingdom

7. Japan Epidemiology

  • 7.1. Assumptions and Rationale
  • 7.2. Total Prevalence of Gastroparesis in Japan
  • 7.3. Type-Specific Prevalence of Gastroparesis in Japan
  • 7.4. Gender-Specific Prevalence of Gastroparesis in Japan
  • 7.5. Severity Specific Prevalence of Gastroparesis in Japan
  • 7.6. Total Diagnosed Prevalence of Gastroparesis in Japan

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Treatment Algorithm for Gastroparesis
  • 8.2. Treatment and Management for Gastroparesis
    • 8.2.1. Dietary Modifications
    • 8.2.2. Pharmacological Treatment
    • 8.2.3. Pyloric Intervention
    • 8.2.4. Gastric Electrical Stimulation

9. Proposed Clinical Guidelines for the Management of Gastroparesis

  • 9.1. Recommendations
  • 9.2. Consensus Guidelines for Clinical Management of Diabetic Gastroparesis

10. Unmet Needs

11. Marketed Products

  • 11.1. Reglan: ANI Pharmaceuticals
    • 11.1.1. Product Description
    • 11.1.2. Regulatory Milestones
    • 11.1.3. Product Profile
  • 11.2. Motilium (Domperidone): Janssen
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Safety and Efficacy
    • 11.2.4. Product Profile

12. Emerging Therapies

  • 12.1. Key Cross Competition
  • 12.2. Relamorelin: Allergan
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Product Profile
  • 12.3. Gimoti (Metoclopramide Nasal Spray): Evoke Pharma
    • 12.3.1. Product Description
    • 12.3.2. Other Developmental Activities
    • 12.3.3. Clinical Development
    • 12.3.4. Safety and Efficacy
    • 12.3.5. Product Profile
  • 12.4. Tradipitant: Vanda Pharmaceuticals
    • 12.4.1. Product Description
    • 12.4.2. Other Developmental Activities
    • 12.4.3. Clinical Development
    • 12.4.4. Safety and Efficacy
    • 12.4.5. Product Profile
  • 12.5. Velusetrag: Theravance Biopharma
    • 12.5.1. Product Description
    • 12.5.2. Other Developmental Activities
    • 12.5.3. Clinical Development
    • 12.5.4. Safety and Efficacy
    • 12.5.5. Product Profile
  • 12.6. CNSA-001: Censa Pharmaceuticals
    • 12.6.1. Product Description
    • 12.6.2. Clinical Development
    • 12.6.3. Product Profile
  • 12.7. Nimacimab: Bird Rock Bio
    • 12.7.1. Product Description
    • 12.7.2. Other Development Activities
    • 12.7.3. Clinical Development
    • 12.7.4. Product Profile
  • 12.8. CIN-102: CinDome Pharma
    • 12.8.1. Product Description
    • 12.8.2. Other Developmental Activities
    • 12.8.3. Clinical Development
    • 12.8.4. Safety and Efficacy
    • 12.8.5. Product Profile
  • 12.9. TAK 906: Takeda (Millennium Pharmaceuticals)
    • 12.9.1. Product Description
    • 12.9.2. Other Developmental Activities
    • 12.9.3. Clinical Development
    • 12.9.4. Safety and Efficacy
    • 12.9.5. Product Profile

13. Gastroparesis: Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Market Size of Gastroparesis in 7MM
  • 13.3. Market Size of Gastroparesis by Therapies in the 7MM

14. United States: Market Outlook

  • 14.1. United States Market Size
    • 14.1.1. Total Market size of Gastroparesis in the United States
    • 14.1.2. Market Size of Gastroparesis by Therapies in the US

15. EU-5 countries: Market Outlook

  • 15.1. Germany Market Size
    • 15.1.1. Total Market size of Gastroparesis in Germany
    • 15.1.2. Market Size of Gastroparesis by therapies in Germany
  • 15.2. France Market Size
    • 15.2.1. Total Market size of Gastroparesis in France
    • 15.2.2. Market Size of Gastroparesis by therapies in France
  • 15.3. Italy Market Size
    • 15.3.1. Total Market size of Gastroparesis in Italy
    • 15.3.2. Market Size of Gastroparesis by therapies in Italy
  • 15.4. Spain Market Size
    • 15.4.1. Total Market size of Gastroparesis in Spain
    • 15.4.2. Market Size of Gastroparesis by therapies in Spain
  • 15.5. United Kingdom Market Size
    • 15.5.1. Total Market size of Gastroparesis in the United Kingdom
    • 15.5.2. Market Size of Gastroparesis by therapies in the UK

16. Japan Market Outlook

  • 16.1. Japan Market Size
    • 16.1.1. Total Market size of Gastroparesis in Japan
    • 16.1.2. Market Size of Gastroparesis by therapies in Japan

17. Market Drivers

18. Market Barriers

19. Appendix

  • 19.1. Report Methodology

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

List of Tables

  • Table 1 Pathogenesis and Etiology of Gastroparesis
  • Table 2 Total Prevalence of Gastroparesis in the 7MM (2017-2028)
  • Table 3 Type-Specific Prevalence of Gastroparesis in the 7MM (2017-2028)
  • Table 4 Gender-Specific Prevalence of Gastroparesis in the 7MM (2017-2028)
  • Table 5 Severity-Specific Prevalence of Gastroparesis in the 7MM (2017-2028)
  • Table 6 Total Diagnosed Prevalent Population of Gastroparesis in the 7MM (2017-2028)
  • Table 7 Total Prevalence of Gastroparesis in the United States (2017-2028)
  • Table 8 Type-Specific Diagnosed Prevalence of Gastroparesis in the United States (2017-2028)
  • Table 9 Gender-Specific Prevalence of Gastroparesis in the US (2017-2028)
  • Table 10 Severity-Specific Prevalence of Gastroparesis in the United States(2017-2028)
  • Table 11 Total Diagnosed Prevalence of Gastroparesis in the United States (2017-2028)
  • Table 12 Total Prevalence of Gastroparesis in Germany (2017-2028)
  • Table 13 Type-Specific Prevalence of Gastroparesis in Germany (2017-2028)
  • Table 14 Gender-Specific Prevalence of Gastroparesis in Germany (2017-2028)
  • Table 15 Severity-Specific Prevalence of Gastroparesis in Germany (2017-2028)
  • Table 16 Total Diagnosed Prevalence of Gastroparesis in Germany (2017-2028)
  • Table 17 Total Prevalence of Gastroparesis in France (2017-2028)
  • Table 18 Type-Specific Prevalence of Gastroparesis in France (2017-2028)
  • Table 19 Gender-Specific Prevalence of Gastroparesis in France (2017-2028)
  • Table 20 Severity-Specific Prevalence of Gastroparesis in France (2017-2028)
  • Table 21 Total Diagnosed Prevalence of Gastroparesis in France (2017-2028)
  • Table 22 Total Prevalence of Gastroparesis in Italy (2017-2028)
  • Table 23 Type-Specific Prevalence of Gastroparesis in Italy (2017-2028)
  • Table 24 Gender-Specific Prevalence of Gastroparesis in Italy (2017-2028)
  • Table 25 Severity-Specific Prevalence of Gastroparesis in Italy (2017-2028)
  • Table 26 Total Diagnosed Prevalence of Gastroparesis in Italy (2017-2028)
  • Table 27 Total Prevalence of Gastroparesis in Spain (2017-2028)
  • Table 28 Type-Specific Prevalence of Gastroparesis in Spain (2017-2028)
  • Table 29 Gender-Specific Prevalence of Gastroparesis in Spain (2017-2028)
  • Table 30 Severity-Specific Prevalence of Gastroparesis in Spain (2017-2028)
  • Table 31 Total Diagnosed Prevalence of Gastroparesis in Spain (2017-2028)
  • Table 32 Total Prevalence of Gastroparesis in the United Kingdom (2017-2028)
  • Table 33 Type-Specific Prevalence of Gastroparesis in the United Kingdom (2017-2028)
  • Table 34 Gender-Specific Prevalence of Gastroparesis in the United Kingdom (2017-2028)
  • Table 35 Severity-Specific Prevalence of Gastroparesis in the United Kingdom (2017-2028)
  • Table 36 Total Diagnosed Prevalence of Gastroparesis in the United Kingdom (2017-2028)
  • Table 37 Total Prevalence of Gastroparesis in Japan (2017-2028)
  • Table 38 Type-Specific Prevalence of Gastroparesis in Japan (2017-2028)
  • Table 39 Gender-Specific Prevalence of Gastroparesis in Japan (2017-2028)
  • Table 40 Severity-Specific Prevalence of Gastroparesis in Japan (2017-2028)
  • Table 41 Total Diagnosed Prevalence of Gastroparesis in Japan (2017-2028)
  • Table 42 Pharmacological Treatment Options for the Management of Diabetic Gastroparesis
  • Table 43 Pharmacological Treatment Options for the Management of Diabetic Gastroparesis
  • Table 44 Pharmacological Treatment Options for the Management of Diabetic Gastroparesis
  • Table 45 Emerging Keycross Competition
  • Table 46 Relamorelin (RM-131), Clinical Trial Description, 2019
  • Table 47 Metoclopramide Nasal Spray; Clinical Trial Description, 2019
  • Table 48 Tradipitant; Clinical Trial Description, 2019
  • Table 49 Velusetrag; Clinical Trial Description, 2019
  • Table 50 CNSA-001, Clinical Trial Description, 2019
  • Table 51 Nimacimab, Clinical Trial Description, 2019
  • Table 52 CIN-102, Clinical Trial Description, 2019
  • Table 53 TAK 906, Clinical Trial Description, 2019
  • Table 54 Market Size of Gastroparesis in 7MM in USD Million (2017-2028)
  • Table 55 Market Size of Gastroparesis by therapies in the 7MM, in USD Million (2017-2028)
  • Table 56 Currently Prescribed Classes and their Side-Effects
  • Table 57 Emerging Therapies Expected to be Launched During Forecast Period (2019-2028) in the United States
  • Table 58 The US Market Size of Gastroparesis in USD Million (2017-2028)
  • Table 59 Market Size of Gastroparesis by therapies in the US, in USD Million (2017-2028)
  • Table 60 Germany Market Size of Gastroparesis in USD Million (2017-2028)
  • Table 61 Market Size of Gastroparesis by therapies in Germany, in USD Million (2017-2028)
  • Table 62 France Market Size of Gastropares is in USD Million (2017-2028)
  • Table 63 Market Size of Gastroparesis by therapies in France, in USD Million (2017-2028)
  • Table 64 Italy Market Size of Gastroparesis in USD Million (2017-2028)
  • Table 65 Market Size of Gastroparesis by therapies in Italy, in USD Million (2017-2028)
  • Table 66 Spain Market Size of Gastroparesis in USD Million (2017-2028)
  • Table 67 Market Size of Gastroparesis by therapies in Spain, in USD Million (2017-2028)
  • Table 68 The UK Market Size of Gastroparesis in USD Million (2017-2028)
  • Table 69 Market Size of Gastroparesis by therapies in the UK, in USD Million (2017-2028)
  • Table 70 Japan Market Size of Gastroparesis in USD Million (2017-2028)
  • Table 71 Market Size of Gastroparesis by therapies in Japan, in USD Million (2017-2028)

List of Figures

  • Figure 1 Types of Gastroparesis Based on Causes
  • Figure 2 Etiologies of Gastroparesis
  • Figure 3 Interaction of Interstitial Cells of Cajal (ICC) Cells and Neuronal Nitric Oxide Synthase (nNOS) Signaling for Normal Gastric Emptying (GE)
  • Figure 4 Mechanisms of Gastric Accommodation and Emptying
  • Figure 5 Diagnosis of Gastroparesis
  • Figure 6 Total Prevalence of Gastroparesis in the 7MM (2017-2028)
  • Figure 7 Type-Specific Prevalence of Gastroparesis in the 7MM (2017-2028)
  • Figure 8 Gender- Specific Prevalence of Gastroparesis in the 7MM(2017-2028)
  • Figure 9 Severity-Specific Prevalence of Gastroparesis in the 7MM (2017-2028)
  • Figure 10 Total Diagnosed Prevalent Population of Gastroparesis in the 7MM (2017-2028)
  • Figure 11 Total Prevalence of Gastroparesis in the United States (2017-2028)
  • Figure 12 Type-Specific Diagnosed Prevalence of Gastroparesis in the United States (2017-2028)
  • Figure 13 Gender- Specific Prevalence of Gastroparesisin the US (2017-2028)
  • Figure 14 Severity-Specific Prevalence of Gastroparesis in the United States (2017-2028)
  • Figure 15 Total Diagnosed Prevalence of Gastroparesis in the United States (2017-2028)
  • Figure 16 Total Prevalence of Gastroparesis in Germany (2017-2028)
  • Figure 17 Type-Specific Prevalence of Gastroparesis in Germany (2017-2028)
  • Figure 18 Gender- Specific Prevalence of Gastroparesis in Germany (2017-2028)
  • Figure 19 Severity-Specific Prevalence of Gastroparesis in Germany (2017-2028)
  • Figure 20 Total Diagnosed Prevalence of Gastroparesis in Germany (2017-2028)
  • Figure 21 Total Prevalence of Gastroparesis in France (2017-2028)
  • Figure 22 Type-Specific Prevalence of Gastroparesis in France (2017-2028)
  • Figure 23 Gender- Specific Prevalence of Gastroparesis in France (2017-2028)
  • Figure 24 Severity-Specific Prevalence of Gastroparesis in France (2017-2028)
  • Figure 25 Total Diagnosed Prevalence of Gastroparesis in France (2017-2028)
  • Figure 26 Total Prevalence of Gastroparesis in Italy (2017-2028)
  • Figure 27 Type-Specific Prevalence of Gastroparesis in Italy (2017-2028)
  • Figure 28 Gender- Specific Prevalence of Gastroparesis in Italy (2017-2028)
  • Figure 29 Severity-Specific Prevalence of Gastroparesis in Italy (2017-2028)
  • Figure 30 Total Diagnosed Prevalence of Gastroparesis in Italy (2017-2028)
  • Figure 31 Total Prevalence of Gastroparesis in Spain (2017-2028)
  • Figure 32 Type-Specific Prevalence of Gastroparesis in Spain (2017-2028)
  • Figure 33 Gender- Specific Prevalence of Gastroparesis in Spain (2017-2028)
  • Figure 34 Severity-Specific Prevalence of Gastroparesis in Spain (2017-2028)
  • Figure 35 Total Diagnosed Prevalence of Gastroparesis in Spain (2017-2028)
  • Figure 36 Total Prevalence of Gastroparesis in the United Kingdom (2017-2028)
  • Figure 37 Type-Specific Prevalence of Gastroparesis in the United Kingdom (2017-2028)
  • Figure 38 Gender- Specific Prevalence of Gastroparesis in the United Kingdom (2017-2028)
  • Figure 39 Severity-Specific Prevalence of Gastroparesis in the United Kingdom (2017-2028)
  • Figure 40 Total Diagnosed Prevalence of Gastroparesis in the United Kingdom (2017-2028)
  • Figure 41 Total Prevalence of Gastroparesis in Japan (2017-2028)
  • Figure 42 Type-Specific Prevalence of Gastroparesis in Japan (2017-2028)
  • Figure 43 Gender- Specific Prevalence of Gastroparesis in Japan (2017-2028)
  • Figure 44 Severity-Specific Prevalence of Gastroparesis in Japan (2017-2028)
  • Figure 45 Total Diagnosed Prevalence of Gastroparesis in Japan (2017-2028)
  • Figure 46 Diagnosis and Management Algorithm for Gastroparesis Syndromes
  • Figure 47 Algorithm for Prokinetic Therapy in Gastroparesis
  • Figure 48 Treatment Algorithm for Gastroparesis
  • Figure 49 Unmet Needs of Gastroparesis
  • Figure 50 Potential Drug-drug Interactions in Gastroparesis
  • Figure 51 Market Size of Gastroparesis in the 7MM in USD Million (2017-2028)
  • Figure 52 Market Size of Gastroparesis by therapies in the 7MM, in USD Million (2017-2028)
  • Figure 53 Market Size of Gastroparesis in the US, USD Millions (2017-2028)
  • Figure 54 Market Size of Gastroparesis by therapies in the United States, in USD Million (2017-2028)
  • Figure 55 Market Size of Gastroparesis in Germany, USD Millions (2017-2028)
  • Figure 56 Market Size of Gastroparesis by therapies in Germany, in USD Million (2017-2028)
  • Figure 57 Market Size of Gastroparesis in France, USD Millions (2017-2028)
  • Figure 58 Market Size of Gastroparesis by therapies in France, in USD Million (2017-2028)
  • Figure 59 Market Size of Gastroparesis in Italy, USD Millions (2017-2028)
  • Figure 60 Market Size of Gastroparesis by therapies in Italy in USD Million (2017-2028)
  • Figure 61 Market Size of Gastroparesis in Spain, USD Millions (2017-2028)
  • Figure 62 Market Size of Gastroparesis by therapies in Spain in USD Million (2017-2028)
  • Figure 63 Market Size of Gastroparesis in the UK, USD Millions (2017-2028)
  • Figure 64 Market Size of Gastroparesis by therapies in the UK in USD Million (2017-2028)
  • Figure 65 Market Size of Gastroparesis in Japan, USD Millions (2017-2028)
  • Figure 66 Market Size of Gastroparesis by therapies in Japan in USD Million (2017-2028)
  • Figure 67 Market Drivers
  • Figure 68 Market Barriers
Back to Top